MINT-LEUCOVORIN 5 MG — DIN 02496828
LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG · MINT PHARMACEUTICALS INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is MINT-LEUCOVORIN?
MINT-LEUCOVORIN 5 MG contains LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02496828, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MINT-LEUCOVORIN used for?
Diminishing toxicity/counteracting impaired methotrexate elimination; treatment of megaloblastic anemias due to folate deficiency (sprue, nutritional deficiency, pregnancy, infancy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Calcium Folinate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Calcium Folinate, across 21 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 3 | 3 | LEDERLE LEUCOVORIN, LEUCOVORIN CALCIUM INJECTION USP | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 3 | 2 | LEUCOVORIN CALCIUM INJECTION | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP LEUCOVORIN, LEUCOVORIN CALCIUM INJECTION USP | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 1 | 1 | RIVA LEUCOVORIN | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-LEUCOVORIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | LEUCOVORIN CALCIUM INJECTION | Sourceable in Canada |
| LEDERLE CYANAMID CANADA INC. | 4 | 0 | LEDERLE LEUCOVORIN 350MG/VIAL, LEDERLE LEUCOVORIN 50MG/VIAL, LEDERLE LEUCOVORIN LIQ 10MG/ML, LEUCOVORIN CALCIUM TAB 5MG | No marketed DIN |
| WYETH-AYERST CANADA INC. | 3 | 0 | LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML, LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL, LEDERLE LEUCOVORIN-PWS IM IV 50MG/VIAL | No marketed DIN |
| DAVID BULL LABORATORIES (PTY) LTD. | 2 | 0 | LEUCOVORIN CA INJ (PHARM. BULK VIAL) 10MG/ML, LEUCOVORIN CALCIUM INJ 10MG/ML | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | LEUCOVORIN CALCIUM INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | HDPE bottles of 24 and 100 tablets. |
| Storage | Not explicitly detailed in provided text (standard section 11 missing specific temp), but typically 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Calcium Folinate |
|---|---|
| ATC code | V03AF03 |
| AHFS class | 91:04.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02496828 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2496828 |
| Brand name | MINT-LEUCOVORIN |
| Generic / active ingredient | LEUCOVORIN (LEUCOVORIN CALCIUM) : 5 MG |
| Market authorization holder | MINT PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | V03AF03 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AF |
| Current status | MARKETED |
| Status date | 12-Jan-2021 |
| Original market date | 2021-01-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Rescue: 15 mg every 6 hours for 10 doses starting 24h after methotrexate. Megaloblastic anemia: up to 15 mg daily. Oral doses >25 mg not recommended due to saturable absorption.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or excipients; Pernicious anemia or other megaloblastic anemias where Vitamin B12 is deficient.
Warnings and precautions
Serious: Use only under expert supervision. Risk of fatal GI toxicity, myelosuppression, and SJS/TEN. May enhance 5-FU toxicity. May mask Vitamin B12 deficiency.
Is Calcium Folinate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 21 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP LEUCOVORIN | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02548208 |
| LEDERLE LEUCOVORIN | 5 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02170493 |
| LEUCOVORIN CALCIUM INJECTION | 1000 MG / 100 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02496925 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02087316 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02480042 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02182998 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | Solution | PFIZER CANADA ULC | MARKETED | 02183005 |
| RIVA LEUCOVORIN | 5 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02493357 |
| LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML | 10 MG | LIQUID | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02170485 |
| LEDERLE LEUCOVORIN 350MG/VIAL | 350 MG | POWDER FOR SOLUTION | LEDERLE CYANAMID CANADA INC. | CANCELLED POST MARKET | 01927442 |
2 · Same class — other molecules in ATC V03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Calcium Folinate | JAMP LEUCOVORIN · LEDERLE LEUCOVORIN · LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML · LEDERLE LEUCOVORIN 350MG/VIAL · +11 more | 21 | 9 | Yes |
| Dexrazoxane | DEXRAZOXANE FOR INJECTION · ZINECARD | 5 | 3 | Yes |
| Mesna | MESNA FOR INJECTION · UROMITEXAN · UROMITEXAN INJ 100MG/ML | 4 | 3 | Yes |
| Rasburicase | FASTURTEC | 2 | 1 | Yes |
| Amifostine | ETHYOL - PWS IV 500MG/VIAL | 1 | 0 | Not in Canada |
| Palifermin | KEPIVANCE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AC | Deferasirox · Deferiprone · Deferoxamine | 57 | 44 |
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AE | Calcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more | 40 | 19 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.